Skip to content
2000
Volume 24, Issue 3
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Schizophrenia remains a therapeutic challenge. For much of its long history, the physiological basis of its symptoms and clinical presentation remained elusive. However, in recent decades, consistent anatomical and metabolic changes have been documented that can also serve as therapeutic targets. An insult to the developing nervous system in the prenatal or neonatal period appears to set the schizophrenic syndrome in motion by preventing the development of the normal circuit balance between inhibitory and excitatory neurons. In time, a reduction in the volume of frontal and temporal grey matter and a decrease in the density of dendritic spines on pyramidal neurons becomes apparent. These anatomical findings are accompanied by a reduced capacity to synthesize GABA, an increased capacity to synthesize and release dopamine, and an increased level of blood cortisol. Treatment with sodium oxybate (SO) (gammahydroxybutyrate) may make it possible to reverse these pathological features of the schizophrenic syndrome, given SO’s potential to increase neuronal levels of GABA, inhibit dopamine release and reduce blood cortisol levels. SO can also serve as a source of energy to promote the growth of the dendritic arbor on excitatory pyramidal neurons and as an antioxidant to enhance the activity of GABAergic inhibitory neurons. In this way, SO may restore the balance between the excitatory pyramidal neurons and the inhibitory GABAergic neurons in schizophrenia. In a short clinical trial, the use of SO to improve the sleep of patients with chronic schizophrenia led to a significant clinical improvement.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X377481250526110256
2025-06-04
2026-03-03

  • From This Site

    /content/journals/cn/10.2174/011570159X377481250526110256
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LehmannH.E. BanT.A. The history of the psychopharmacology of schizophrenia.Can. J. Psychiatry199742215216210.1177/070674379704200205 9067064
     [Google Scholar]
  2. HarrisonP.J. The neuropathology of schizophrenia.Brain1999122459362410.1093/brain/122.4.593 10219775
     [Google Scholar]
  3. BenesF. Emerging principles of altered neural circuitry in schizophrenia.Brain Res. Brain Res. Rev.2000312-325126910.1016/S0165‑0173(99)00041‑7 10719152
     [Google Scholar]
  4. LewisD.A. HashimotoT. VolkD.W. Cortical inhibitory neurons and schizophrenia.Nat. Rev. Neurosci.20056431232410.1038/nrn1648 15803162
     [Google Scholar]
  5. HarrisonP.J. Postmortem studies in schizophrenia.Dialogues Clin. Neurosci.20002434935710.31887/DCNS.2000.2.4/pharrison 22033474
     [Google Scholar]
  6. HoltzmanC.W. TrotmanH.D. GouldingS.M. RyanA.T. MacDonaldA.N. ShapiroD.I. BrasfieldJ.L. WalkerE.F. Stress and neurodevelopmental processes in the emergence of psychosis.Neuroscience201324917219110.1016/j.neuroscience.2012.12.017 23298853
     [Google Scholar]
  7. TakahashiT. SuzukiM. Brain morphologic changes in early stages of psychosis: Implications for clinical application and early intervention.Psychiatry Clin. Neurosci.201872855657110.1111/pcn.12670 29717522
     [Google Scholar]
  8. TakahashiT. HiguchiY. KomoriY. NishiyamaS. TakayanagiY. SasabayashiD. KidoM. FuruichiA. NishikawaY. NakamuraM. NoguchiK. SuzukiM. Pituitary volume and socio-cognitive functions in individuals at risk of psychosis and patients with schizophrenia.Front. Psychiatry2018957410.3389/fpsyt.2018.00574 30473669
     [Google Scholar]
  9. TakahashiT. SuzukiM. VelakoulisD. LorenzettiV. SoulsbyB. ZhouS.Y. NakamuraK. SetoH. KurachiM. PantelisC. Increased pituitary volume in schizophrenia spectrum disorders.Schizophr. Res.20091081-311412110.1016/j.schres.2008.12.016 19162445
     [Google Scholar]
  10. ThalhammerM. SchulzJ. ScheulenF. OubaggiM.E.M. KirschnerM. KaiserS. SchmidtA. BorgwardtS. AvramM. BrandlF. SorgC. SorgC. Distinct volume alterations of thalamic nuclei across the schizophrenia spectrum.Schizophr. Bull.20245051208122210.1093/schbul/sbae037 38577901
     [Google Scholar]
  11. Fusar-PoliP. BorgwardtS. CresciniA. DesteG. KemptonM.J. LawrieS. Mc GuireP. SacchettiE. Neuroanatomy of vulnerability to psychosis: A voxel-based meta-analysis.Neurosci. Biobehav. Rev.20113551175118510.1016/j.neubiorev.2010.12.005 21168439
     [Google Scholar]
  12. HulshoffP.H.E. KahnR.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia.Schizophr. Bull.200734235436610.1093/schbul/sbm168 18283048
     [Google Scholar]
  13. BorgwardtS.J. PicchioniM.M. EttingerU. ToulopoulouT. MurrayR. McGuireP.K. Regional gray matter volume in monozygotic twins concordant and discordant for schizophrenia.Biol. Psychiatry2010671095696410.1016/j.biopsych.2009.10.026 20006324
     [Google Scholar]
  14. BroschK. SteinF. SchmittS. PfarrJ.K. RingwaldK.G. Thomas-OdenthalF. MellerT. SteinsträterO. WaltemateL. LemkeH. MeinertS. WinterA. BreuerF. ThielK. GrotegerdD. HahnT. JansenA. DannlowskiU. KrugA. NenadićI. KircherT. Reduced hippocampal gray matter volume is a common feature of patients with major depression, bipolar disorder, and schizophrenia spectrum disorders.Mol. Psychiatry202227104234424310.1038/s41380‑022‑01687‑4 35840798
     [Google Scholar]
  15. KimE.J. PellmanB. KimJ.J. Stress effects on the hippocampus: A critical review.Learn. Mem.201522941141610.1101/lm.037291.114 26286651
     [Google Scholar]
  16. BrownE.S. Jeon-SlaughterH. LuH. JamadarR. IssacS. ShadM. DennistonD. TammingaC. NakamuraA. ThomasB.P. Hippocampal volume in healthy controls given 3-day stress doses of hydrocortisone.Neuropsychopharmacology20154051216122110.1038/npp.2014.307 25409592
     [Google Scholar]
  17. RingwaldK.G. PfarrJ.K. SteinF. BroschK. MellerT. Thomas-OdenthalF. MeinertS. WaltemateL. BreuerF. WinterA. LemkeH. GrotegerdD. ThielK. BauerJ. HahnT. JansenA. DannlowskiU. KrugA. NenadićI. KircherT. Association between stressful life events and grey matter volume in the medial prefrontal cortex: A 2‐year longitudinal study.Hum. Brain Mapp.202243113577358410.1002/hbm.25869 35411559
     [Google Scholar]
  18. CullenA.E. FisherH.L. GulletN. FraserE.R. RobertsR.E. ZahidU. ToM. YapN.H. ZunszainP.A. ParianteC.M. WoodS.J. McGuireP. MurrayR.M. MondelliV. LaurensK.R. Cortisol levels in childhood associated with emergence of attenuated psychotic symptoms in early adulthood.Biol. Psychiatry202291222623510.1016/j.biopsych.2021.08.009 34715990
     [Google Scholar]
  19. PruessnerM. CullenA.E. AasM. WalkerE.F. The neural diathesis-stress model of schizophrenia revisited: An update on recent findings considering illness stage and neurobiological and methodological complexities.Neurosci. Biobehav. Rev.20177319121810.1016/j.neubiorev.2016.12.013 27993603
     [Google Scholar]
  20. AymerichC. PedruzoB. PachoM. LabordaM. HerreroJ. PillingerT. McCutcheonR.A. Alonso-AlconadaD. BordenaveM. Martínez-QuerolM. ArnaizA. LabadJ. Fusar-PoliP. González-TorresM.Á. CatalanA. Prolactin and morning cortisol concentrations in antipsychotic naïve first episode psychosis: A systematic review and meta-analysis.Psychoneuroendocrinology202315010604910.1016/j.psyneuen.2023.106049
     [Google Scholar]
  21. MisiakB. PruessnerM. SamochowiecJ. WiśniewskiM. ReginiaA. StańczykiewiczB. A meta-analysis of blood and salivary cortisol levels in first-episode psychosis and high-risk individuals.Front. Neuroendocrinol.20216210093010.1016/j.yfrne.2021.100930 34171354
     [Google Scholar]
  22. HubbardD.B. MillerB.J. Meta-analysis of blood cortisol levels in individuals with first-episode psychosis.Psychoneuroendocrinology201910426927510.1016/j.psyneuen.2019.03.014 30909008
     [Google Scholar]
  23. BenesF.M. LimB. MatzilevichD. WalshJ.P. SubburajuS. MinnsM. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars.Proc. Natl. Acad. Sci. USA200710424101641016910.1073/pnas.0703806104 17553960
     [Google Scholar]
  24. CurleyA.A. EgganS.M. LazarusM.S. HuangZ.J. VolkD.W. LewisD.A. Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: Implications for schizophrenia.Neurobiol. Dis.20135017918610.1016/j.nbd.2012.10.018 23103418
     [Google Scholar]
  25. ThompsonM. WeickertC.S. WyattE. WebsterM.J. Decreased glutamic acid decarboxylase67 mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders.J. Psychiatr. Res.2009431197097710.1016/j.jpsychires.2009.02.005 19321177
     [Google Scholar]
  26. BenesF.M. Amygdalocortical circuitry in schizophrenia: From circuits to molecules.Neuropsychopharmacology201035123925710.1038/npp.2009.116 19727065
     [Google Scholar]
  27. LauC.G. MurthyV.N. Activity-dependent regulation of inhibition via GAD67.J. Neurosci.201232258521853110.1523/JNEUROSCI.1245‑12.2012 22723692
     [Google Scholar]
  28. MartinD.L. RimvallK. Regulation of γ‐aminobutyric acid synthesis in the brain.J. Neurochem.199360239540710.1111/j.1471‑4159.1993.tb03165.x
     [Google Scholar]
  29. AndersenJ.V. SchousboeA. WellendorphP. Astrocytes regulate inhibitory neurotransmission through GABA uptake, metabolism, and recycling.Essays Biochem.2023671779110.1042/EBC20220208 36806927
     [Google Scholar]
  30. AndersenJ.V. SchousboeA. Glial glutamine homeostasis in health and disease.Neurochem. Res.20234841100112810.1007/s11064‑022‑03771‑1 36322369
     [Google Scholar]
  31. DienelS.J. LewisD.A. Alterations in cortical interneurons and cognitive function in schizophrenia.Neurobiol. Dis.201913110420810.1016/j.nbd.2018.06.020 29936230
     [Google Scholar]
  32. DienelS.J. FishK.N. LewisD.A. The nature of prefrontal cortical gaba neuron alterations in schizophrenia: Markedly lower somatostatin and parvalbumin gene expression without missing neurons.Am. J. Psychiatry2023180749550710.1176/appi.ajp.20220676 37073488
     [Google Scholar]
  33. GeorgievD. YoshiharaT. KawabataR. MatsubaraT. TsubomotoM. MinabeY. LewisD.A. HashimotoT. Cortical gene expression after a conditional knockout of 67 kDa glutamic acid decarboxylase in parvalbumin neurons.Schizophr. Bull.2016424992100210.1093/schbul/sbw022 26980143
     [Google Scholar]
  34. KarolewiczB. MaciagD. O’DwyerG. StockmeierC.A. FeyissaA.M. RajkowskaG. Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression.Int. J. Neuropsychopharmacol.201013441142010.1017/S1461145709990587 20236554
     [Google Scholar]
  35. DienelS.J. SchoonoverK.E. LewisD.A. Cognitive dysfunction and prefrontal cortical circuit alterations in schizophrenia: Developmental trajectories.Biol. Psychiatry202292645045910.1016/j.biopsych.2022.03.002 35568522
     [Google Scholar]
  36. SchoonoverK.E. DienelS.J. LewisD.A. Prefrontal cortical alterations of glutamate and GABA neurotransmission in schizophrenia: Insights for rational biomarker development.Biomark Neuropsychiatry2020310001510.1016/j.bionps.2020.100015 32656540
     [Google Scholar]
  37. GlausierJ.R. EnwrightJ.F. LewisD.A. PhD. LewisD.A. Diagnosis- and cell type-specific mitochondrial functional pathway signatures in schizophrenia and bipolar disorder.Am. J. Psychiatry2020177121140115010.1176/appi.ajp.2020.19111210 33115248
     [Google Scholar]
  38. SchoonoverK.E. MillerN.E. FishK.N. LewisD.A. Scaling of smaller pyramidal neuron size and lower energy production in schizophrenia.Neurobiol. Dis.202419110639410.1016/j.nbd.2023.106394 38176569
     [Google Scholar]
  39. ChungD.W. FishK.N. LewisD.A. LewisD.A. Pathological basis for deficient excitatory drive to cortical parvalbumin interneurons in schizophrenia.Am. J. Psychiatry2016173111131113910.1176/appi.ajp.2016.16010025 27444795
     [Google Scholar]
  40. MallyaA.P. DeutchA.Y. (Micro)Glia as effectors of cortical volume loss in schizophrenia.Schizophr. Bull.201844594895710.1093/schbul/sby088 30124942
     [Google Scholar]
  41. MacDonaldM.L. AlhassanJ. NewmanJ.T. RichardM. GuH. KellyR.M. SampsonA.R. FishK.N. PenzesP. WillsZ.P. LewisD.A. SweetR.A. Selective loss of smaller spines in schizophrenia.Am. J. Psychiatry2017174658659410.1176/appi.ajp.2017.16070814 28359200
     [Google Scholar]
  42. FeinbergI. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?J. Psychiatr. Res.198217431933410.1016/0022‑3956(82)90038‑3 7187776
     [Google Scholar]
  43. BollingerJ.L. WohlebE.S. The formative role of microglia in stress-induced synaptic deficits and associated behavioral consequences.Neurosci. Lett.201971113436910.1016/j.neulet.2019.134369 31422099
     [Google Scholar]
  44. HowesO.D. OnwordiE.C. The synaptic hypothesis of schizophrenia version III: A master mechanism.Mol. Psychiatry20232851843185610.1038/s41380‑023‑02043‑w 37041418
     [Google Scholar]
  45. WangJ. ChenH.S. LiH.H. WangH.J. ZouR.S. LuX.J. WangJ. NieB.B. WuJ.F. LiS. ShanB.C. WuP.F. LongL.H. HuZ.L. ChenJ.G. WangF. Microglia-dependent excessive synaptic pruning leads to cortical underconnectivity and behavioral abnormality following chronic social defeat stress in mice.Brain Behav. Immun.2023109233610.1016/j.bbi.2022.12.019 36581303
     [Google Scholar]
  46. JenkinsA.K. LewisD.A. VolkD.W. Altered expression of microglial markers of phagocytosis in schizophrenia.Schizophr. Res.2023251222910.1016/j.schres.2022.12.005 36527956
     [Google Scholar]
  47. GlausierJ.R. LewisD.A. Dendritic spine pathology in schizophrenia.Neuroscience20132519010710.1016/j.neuroscience.2012.04.044 22546337
     [Google Scholar]
  48. SanacoraG. YanZ. PopoliM. The stressed synapse 2.0: Pathophysiological mechanisms in stress-related neuropsychiatric disorders.Nat. Rev. Neurosci.20222328610310.1038/s41583‑021‑00540‑x 34893785
     [Google Scholar]
  49. YuenE.Y. WeiJ. LiuW. ZhongP. LiX. YanZ. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex.Neuron201273596297710.1016/j.neuron.2011.12.033 22405206
     [Google Scholar]
  50. CooperM.A. KoleskeA.J. ManuscriptA. Ablation of ErbB4 from excitatory neurons leads to reduced dendritic spine density in mouse prefrontal cortex.J. Comp. Neurol.2014522143351336210.1002/cne.23615 24752666
     [Google Scholar]
  51. PopovV.I. MedvedevN.I. PatrushevI.V. Ignat’evD.A. MorenkovE.D. StewartM.G. Reversible reduction in dendritic spines in CA1 of rat and ground squirrel subjected to hypothermia–normothermia in vivo: A three-dimensional electron microscope study.Neuroscience2007149354956010.1016/j.neuroscience.2007.07.059 17919827
     [Google Scholar]
  52. RobertsR.C. Postmortem studies on mitochondria in schizophrenia.Schizophr. Res.2017187172510.1016/j.schres.2017.01.056 28189530
     [Google Scholar]
  53. TownsendL. PillingerT. SelvaggiP. VeroneseM. TurkheimerF. HowesO. Brain glucose metabolism in schizophrenia: A systematic review and meta-analysis of 18DG-PET studies in schizophrenia.Psychol. Med.202353114880489710.1017/S003329172200174X 35730361
     [Google Scholar]
  54. HyderF. PatelA.B. GjeddeA. RothmanD.L. BeharK.L. ShulmanR.G. Neuronal-glial glucose oxidation and glutamatergic-GABAergic function.J. Cereb. Blood Flow Metab.200626786587710.1038/sj.jcbfm.9600263 16407855
     [Google Scholar]
  55. RothmanD.L. BeharK.L. DienelG.A. Mechanistic stoichiometric relationship between the rates of neurotransmission and neuronal glucose oxidation: Reevaluation of and alternatives to the pseudo- malate- aspartate shuttle model.J. Neurochem.2022137 36089566
     [Google Scholar]
  56. HertzL. ChenY. Integration between glycolysis and glutamate-glutamine cycle flux may explain preferential glycolytic increase during brain activation, requiring glutamate.Front. Integr. Nuerosci.2017111810.3389/fnint.2017.00018 28890689
     [Google Scholar]
  57. MishraP.K. AdusumilliM. DeolalP. MasonG.F. KumarA. PatelA.B. Impaired neuronal and astroglial metabolic activity in chronic unpredictable mild stress model of depression: Reversal of behavioral and metabolic deficit with lanicemine.Neurochem. Int.202013710475010.1016/j.neuint.2020.104750 32360130
     [Google Scholar]
  58. OrhanF. Fatouros-BergmanH. GoinyM. MalmqvistA. PiehlF. CervenkaS. CollsteK. VictorssonP. SellgrenC.M. FlycktL. ErhardtS. EngbergG. CSF GABA is reduced in first-episode psychosis and associates to symptom severity.Mol. Psychiatry20182351244125010.1038/mp.2017.25 28289277
     [Google Scholar]
  59. FrankleW.G. ChoR.Y. PrasadK.M. MasonN.S. ParisJ. HimesM.L. WalkerC. LewisD.A. NarendranR. In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients.Am. J. Psychiatry2015172111148115910.1176/appi.ajp.2015.14081031 26133962
     [Google Scholar]
  60. GodlewskaB.R. MinichinoA. EmirU. AngelescuI. LennoxB. MicunovicM. HowesO. CowenP.J. Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case–control study at 7T.Transl. Psychiatry202111136710.1038/s41398‑021‑01477‑6 34226485
     [Google Scholar]
  61. LavigneK.M. KanagasabaiK. PalaniyappanL. Ultra-high field neuroimaging in psychosis: A narrative review.Front. Psychiatry20221399437299437210.3389/fpsyt.2022.994372 36506432
     [Google Scholar]
  62. MarsmanA. MandlR.C.W. KlompD.W.J. BohlkenM.M. BoerV.O. AndreychenkoA. CahnW. KahnR.S. LuijtenP.R. Hulshoff PolH.E. GABA and glutamate in schizophrenia: A 7T 1H-MRS study.Neuroimage Clin.2014639840710.1016/j.nicl.2014.10.005 25379453
     [Google Scholar]
  63. ReidM.S. TaftiM. NishinoS. SampathkumaranR. SiegelJ.M. MignotE. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine.Brain Res.199673318310010.1016/0006‑8993(96)00541‑0 8891251
     [Google Scholar]
  64. ThakkarK.N. RöslerL. WijnenJ.P. BoerV.O. KlompD.W.J. CahnW. KahnR.S. NeggersS.F.W. 7T proton magnetic resonance spectroscopy of gamma-aminobutyric acid, glutamate, and glutamine reveals altered concentrations in patients with schizophrenia and healthy siblings.Biol. Psychiatry201781652553510.1016/j.biopsych.2016.04.007 27316853
     [Google Scholar]
  65. WangA.M. PradhanS. CoughlinJ.M. TrivediA. DuBoisS.L. CrawfordJ.L. SedlakT.W. NuciforaF.C. NestadtG. NuciforaL.G. SchretlenD.J. SawaA. BarkerP.B. Assessing brain metabolism With 7-T proton magnetic resonance spectroscopy in patients with first-episode psychosis.JAMA Psychiatry201976331432310.1001/jamapsychiatry.2018.3637 30624573
     [Google Scholar]
  66. WijtenburgS.A. WangM. KorenicS.A. ChenS. BarkerP.B. RowlandL.M. Metabolite alterations in adults with schizophrenia, first degree relatives, and healthy controls: A multi-region 7T MRS study.Front. Psychiatry20211265645910.3389/fpsyt.2021.656459 34093272
     [Google Scholar]
  67. ButterfieldD.A. HalliwellB. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.Nat. Rev. Neurosci.201920314816010.1038/s41583‑019‑0132‑6 30737462
     [Google Scholar]
  68. PrabakaranS. SwattonJ.E. RyanM.M. HuffakerS.J. HuangJ.T-J. GriffinJ.L. WaylandM. FreemanT. DudbridgeF. LilleyK.S. KarpN.A. HesterS. TkachevD. MimmackM.L. YolkenR.H. WebsterM.J. TorreyE.F. BahnS. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress.Mol. Psychiatry200497684697, 64310.1038/sj.mp.400151115098003
     [Google Scholar]
  69. Martins-de-SouzaD. MaccarroneG. WobrockT. ZerrI. GormannsP. ReckowS. FalkaiP. SchmittA. TurckC.W. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia.J. Psychiatr. Res.201044161176118910.1016/j.jpsychires.2010.04.014 20471030
     [Google Scholar]
  70. SydnorV.J. RoalfD.R. A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk.Schizophr. Res.2020226616910.1016/j.schres.2020.06.028 32723493
     [Google Scholar]
  71. YangK. LongoL. NaritaZ. CascellaN. NuciforaF.C. CoughlinJ.M. NestadtG. SedlakT.W. MihaljevicM. WangM. KenkareA. NagpalA. SethiM. KellyA. Di CarloP. KamathV. FariaA. BarkerP. SawaA. A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance.Mol. Psychiatry20222721184119110.1038/s41380‑021‑01331‑7 34642460
     [Google Scholar]
  72. DwirD. KhadimallahI. XinL. RahmanM. DuF. ÖngürD. DoK.Q. Redox and immune signaling in schizophrenia: New therapeutic potential.Int. J. Neuropsychopharmacol.202326530932110.1093/ijnp/pyad012 36975001
     [Google Scholar]
  73. ZafirA. BanuN. Modulation of in vivo oxidative status by exogenous corticosterone and restraint stress in rats.Stress200912216717710.1080/10253890802234168 18850490
     [Google Scholar]
  74. CuenodM. SteulletP. CabungcalJ.H. DwirD. KhadimallahI. KlauserP. ConusP. DoK.Q. Caught in vicious circles: A perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia.Mol. Psychiatry20222741886189710.1038/s41380‑021‑01374‑w 34759358
     [Google Scholar]
  75. BerrettaS. PantazopoulosH. MarkotaM. BrownC. BatzianouliE.T. Losing the sugar coating: Potential impact of perineuronal net abnormalities on interneurons in schizophrenia.Schizophr. Res.20151671-3182710.1016/j.schres.2014.12.040 25601362
     [Google Scholar]
  76. EnwrightJ.F. SanapalaS. FoglioA. BerryR. FishK.N. LewisD.A. Reduced labeling of parvalbumin neurons and perineuronal nets in the dorsolateral prefrontal cortex of subjects with schizophrenia.Neuropsychopharmacology20164192206221410.1038/npp.2016.24 26868058
     [Google Scholar]
  77. CabungcalJ.H. SteulletP. KraftsikR. CuenodM. DoK.Q. Early-life insults impair parvalbumin interneurons via oxidative stress: Reversal by N-acetylcysteine.Biol. Psychiatry201373657458210.1016/j.biopsych.2012.09.020 23140664
     [Google Scholar]
  78. BeerakaN.M. Avila-RodriguezM.F. AlievG. Recent reports on redox stress-induced mitochondrial DNA variations, neuroglial interactions, and NMDA receptor system in pathophysiology of schizophrenia.Mol. Neurobiol.20225942472249610.1007/s12035‑021‑02703‑4 35083660
     [Google Scholar]
  79. BaxterP.S. BellK.F.S. HaselP. KaindlA.M. FrickerM. ThomsonD. CreganS.P. GillingwaterT.H. HardinghamG.E. Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system.Nat. Commun.201561676110.1038/ncomms7761 25854456
     [Google Scholar]
  80. PapadiaS. Soriano. X.; Léveillé, F.; Martel, M-A.; Dakin, K.A.; Hansen, H.H.; Kaindl, A.; Sifringer, M.; Fowler, J.; Stefovska, V. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses.Nat. Neurosci.200811447648710.1038/nn2071 18344994
     [Google Scholar]
  81. BehrensM.M. AliS.S. DaoD.N. LuceroJ. ShekhtmanG. QuickK.L. DuganL.L. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase.Science200731858561645164710.1126/science.1148045
     [Google Scholar]
  82. BehrensM.M. SejnowskiT.J. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?Neuropharmacology200957319320010.1016/j.neuropharm.2009.06.002 19523965
     [Google Scholar]
  83. SchiavoneS. SorceS. Dubois-DauphinM. JaquetV. ColaiannaM. ZottiM. CuomoV. TrabaceL. KrauseK.H. Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats.Biol. Psychiatry200966438439210.1016/j.biopsych.2009.04.033 19559404
     [Google Scholar]
  84. McBeanG. Cysteine, Glutathione, and thiol redox balance in astrocytes.Antioxidants201763627510.3390/antiox6030062 28771170
     [Google Scholar]
  85. TosicM. OttJ. BarralS. BovetP. DeppenP. GheorghitaF. MattheyM.L. ParnasJ. PreisigM. SaragaM. SolidaA. TimmS. WangA.G. WergeT. CuénodM. Quang DoK. Schizophrenia and oxidative stress: Glutamate cysteine ligase modifier as a susceptibility gene.Am. J. Hum. Genet.200679358659210.1086/507566 16909399
     [Google Scholar]
  86. GraceA.A. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression.Nat. Rev. Neurosci.201617852453210.1038/nrn.2016.57 27256556
     [Google Scholar]
  87. HradetzkyE. SandersonT.M. TsangT.M. SherwoodJ.L. FitzjohnS.M. LakicsV. MalikN. SchoeffmannS. O’NeillM.J. ChengT.M.K. HarrisL.W. RahmouneH. GuestP.C. SherE. CollingridgeG.L. HolmesE. TricklebankM.D. BahnS. The methylazoxymethanol acetate (MAM-E17) rat model: Molecular and functional effects in the hippocampus.Neuropsychopharmacology201237236437710.1038/npp.2011.219 21956444
     [Google Scholar]
  88. FonnumF. LockE.A. The contributions of excitotoxicity, glutathione depletion and DNA repair in chemically induced injury to neurones: exemplified with toxic effects on cerebellar granule cells.J. Neurochem.200488351353110.1046/j.1471‑4159.2003.02211.x 14720201
     [Google Scholar]
  89. LodgeD.J. GraceA.A. Gestational methylazoxymethanol acetate administration: A developmental disruption model of schizophrenia.Behav. Brain Res.2009204230631210.1016/j.bbr.2009.01.031 19716984
     [Google Scholar]
  90. MooreH. JentschJ.D. GhajarniaM. GeyerM.A. GraceA.A. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: Implications for the neuropathology of schizophrenia.Biol. Psychiatry200660325326410.1016/j.biopsych.2006.01.003 16581031
     [Google Scholar]
  91. GillK.M. GraceA.A. Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model.Int. J. Neuropsychopharmacol.201417101609161910.1017/S146114571400056X 24787547
     [Google Scholar]
  92. DuY. GraceA.A. Loss of parvalbumin in the hippocampus of MAM schizophrenia model rats is attenuated by peripubertal diazepam.Int. J. Neuropsychopharmacol.20161911pyw06510.1093/ijnp/pyw065 27432008
     [Google Scholar]
  93. PhensyA. DriskillC. LindquistK. GuoL. JeevakumarV. FowlerB. DuH. KroenerS. Antioxidant treatment in male mice prevents mitochondrial and synaptic changes in an NMDA receptor dysfunction model of schizophrenia.eNeuro201744eCollection 2017.10.1523/ENEURO.0081‑17.201728819639
     [Google Scholar]
  94. CabungcalJ.H. CounotteD.S. LewisE.M. TejedaH.A. PiantadosiP. PollockC. CalhoonG.G. SullivanE.M. PresgravesE. KilJ. HongL.E. CuenodM. DoK.Q. O’DonnellP. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia.Neuron20148351073108410.1016/j.neuron.2014.07.028 25132466
     [Google Scholar]
  95. GomesF.V. GraceA.A. Adolescent stress as a driving factor for schizophrenia development - A basic science perspective.Schizophr. Bull.201743348648910.1093/schbul/sbx033 28419390
     [Google Scholar]
  96. McCutcheonR.A. Abi-DarghamA. HowesO.D. Schizophrenia, dopamine and the striatum: From biology to symptoms.Trends Neurosci.201942320522010.1016/j.tins.2018.12.004 30621912
     [Google Scholar]
  97. HowesO.D. BukalaB.R. BeckK. Schizophrenia: From neurochemistry to circuits, symptoms and treatments.Nat. Rev. Neurol.2024201223510.1038/s41582‑023‑00904‑0 38110704
     [Google Scholar]
  98. McCutcheonR.A. KeefeR.S.E. McGuireP.K. Cognitive impairment in schizophrenia: Aetiology, pathophysiology, and treatment.Mol. Psychiatry20232851902191810.1038/s41380‑023‑01949‑9 36690793
     [Google Scholar]
  99. SonnenscheinS.F. GomesF.V. GraceA.A. Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia.Front. Psychiatry20201161310.3389/fpsyt.2020.00613 32719622
     [Google Scholar]
  100. LodgeD.J. GraceA.A. The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons.Proc. Natl. Acad. Sci. USA2006103135167517210.1073/pnas.0510715103 16549786
     [Google Scholar]
  101. FlorescoS.B. WestA.R. AshB. MooreH. GraceA.A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission.Nat. Neurosci.20036996897310.1038/nn1103 12897785
     [Google Scholar]
  102. GraceA.A. GomesF.V. The circuitry of dopamine system regulation and its disruption in schizophrenia: Insights into treatment and prevention.Schizophr. Bull.201945114815710.1093/schbul/sbx199 29385549
     [Google Scholar]
  103. Fuente-SandovalC. León-OrtizP. FavilaR. StephanoS. MamoD. Ramírez-BermúdezJ. Graff-GuerreroA. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.Neuropsychopharmacology20113691781179110.1038/npp.2011.65 21508933
     [Google Scholar]
  104. de la Fuente-SandovalC. León-OrtizP. AzcárragaM. StephanoS. FavilaR. Díaz-GalvisL. Alvarado-AlanisP. Ramírez-BermúdezJ. Graff-GuerreroA. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: A longitudinal proton magnetic resonance spectroscopy study.JAMA Psychiatry201370101057106610.1001/jamapsychiatry.2013.289 23966023
     [Google Scholar]
  105. HeckersS. RauchS. GoffD. SavageC. SchacterD. FischmanA. AlpertN. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia.Nat. Neurosci.19981431832310.1038/1137 10195166
     [Google Scholar]
  106. McHugoM. TalatiP. ArmstrongK. VandekarS.N. BlackfordJ.U. WoodwardN.D. HeckersS. Hyperactivity and reduced activation of anterior hippocampus in early psychosis.Am. J. Psychiatry2019176121030103810.1176/appi.ajp.2019.19020151 31623459
     [Google Scholar]
  107. ZimmermanE.C. GraceA.A. The nucleus reuniens of the midline thalamus gates prefrontal-hippocampal modulation of ventral tegmental area dopamine neuron activity.J. Neurosci.201636348977898410.1523/JNEUROSCI.1402‑16.2016 27559178
     [Google Scholar]
  108. ZimmermanE.C. GraceA.A. Prefrontal cortex modulates firing pattern in the nucleus reuniens of the midline thalamus via distinct corticothalamic pathways.Eur. J. Neurosci.201848103255327210.1111/ejn.14111 30107061
     [Google Scholar]
  109. SteulletP. CabungcalJ-H. BukhariS.A. ArdeltM.I. PantazopoulosH. HamatiF. SaltT.E. CuenodM. DoK.Q. BerrettaS. The thalamic reticular nucleus in schizophrenia and bipolar disorder: Role of parvalbumin-expressing neuron networks and oxidative stress.Mol. Psychiatry201823102057206510.1038/mp.2017.230 29180672
     [Google Scholar]
  110. ZhuX. CabungcalJ.H. CuenodM. UlianaD.L. DoK.Q. GraceA.A. Thalamic reticular nucleus impairments and abnormal prefrontal control of dopamine system in a developmental model of schizophrenia: Prevention by N-acetylcysteine.Mol. Psychiatry202126127679768910.1038/s41380‑021‑01198‑8 34193975
     [Google Scholar]
  111. GraceA.A. UlianaD.L. Insights into the mechanism of action of antipsychotic drugs derived from animal models: Standard of care versus novel targets.Int. J. Mol. Sci.202324151237410.3390/ijms241512374 37569748
     [Google Scholar]
  112. KaarS.J. NatesanS. McCutcheonR. HowesO.D. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology.Neuropharmacology202017210770410.1016/j.neuropharm.2019.107704 31299229
     [Google Scholar]
  113. SonnenscheinS.F. GillK.M. GraceA.A. State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia.Neuropsychopharmacology201944357258010.1038/s41386‑018‑0219‑1 30267014
     [Google Scholar]
  114. PaulS.M. YohnS.E. PopiolekM. MillerA.C. FelderC.C. MillerA.C. PhD. FelderC.C. PhD. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia.Am. J. Psychiatry2022179961162710.1176/appi.ajp.21101083 35758639
     [Google Scholar]
  115. PaulS.M. YohnS.E. BrannanS.K. NeugebauerN.M. BreierA. Muscarinic receptor activators as novel treatments for schizophrenia.Biol. Psychiatry202496862763710.1016/j.biopsych.2024.03.014 38537670
     [Google Scholar]
  116. ShekharA. PotterW.Z. LightfootJ. LienemannJ. DubéS. MallinckrodtC. BymasterF.P. McKinzieD.L. FelderC.C. PhD. BymasterF.P. ScM. MckinzieD.L. PhD. FelderC.C. PhD. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.Am. J. Psychiatry200816581033103910.1176/appi.ajp.2008.06091591 18593778
     [Google Scholar]
  117. JeonJ. DenckerD. WörtweinG. WoldbyeD.P.D. CuiY. DavisA.A. LeveyA.I. SchützG. SagerT.N. MørkA. LiC. DengC.X. Fink-JensenA. WessJ. A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors.J. Neurosci.20103062396240510.1523/JNEUROSCI.3843‑09.2010 20147565
     [Google Scholar]
  118. FosterD.J. WilsonJ.M. RemkeD.H. MahmoodM.S. UddinM.J. WessJ. PatelS. MarnettL.J. NiswenderC.M. JonesC.K. XiangZ. LindsleyC.W. RookJ.M. ConnP.J. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release.Neuron20169161244125210.1016/j.neuron.2016.08.017 27618677
     [Google Scholar]
  119. GomesF.V. GraceA.A. Beyond dopamine receptor antagonism: New targets for schizophrenia treatment and prevention.Int. J. Mol. Sci.2021229446710.3390/ijms22094467 33922888
     [Google Scholar]
  120. KohlmeierK.A. IshibashiM. WessJ. BickfordM.E. LeonardC.S. Knockouts reveal overlapping functions of M2 and M4 muscarinic receptors and evidence for a local glutamatergic circuit within the laterodorsal tegmental nucleus.J. Neurophysiol.2012108102751276610.1152/jn.01120.2011 22956788
     [Google Scholar]
  121. KohlmeierK.A. KristiansenU. GABAergic actions on cholinergic laterodorsal tegmental neurons: Implications for control of behavioral state.Neuroscience2010171381282910.1016/j.neuroscience.2010.09.034 20884335
     [Google Scholar]
  122. FernandezS.P. BroussotL. MartiF. ContesseT. MouskaX. Soiza-ReillyM. MarieH. FaureP. BarikJ. Mesopontine cholinergic inputs to midbrain dopamine neurons drive stress-induced depressive-like behaviors.Nat. Commun.201891444910.1038/s41467‑018‑06809‑7 30361503
     [Google Scholar]
  123. BarikJ. MartiF. MorelC. FernandezS.P. Chronic stress triggers social aversion via glucocorticoid receptor in dopaminoceptive neurons.Science2013339611733233510.1126/science.1226767
     [Google Scholar]
  124. KohlmeierK.A. VardarB. ChristensenM.H. γ-Hydroxybutyric acid induces actions via the GABAB receptor in arousal and motor control-related nuclei: Implications for therapeutic actions in behavioral state disorders.Neuroscience201324826127710.1016/j.neuroscience.2013.06.011 23791974
     [Google Scholar]
  125. MaddenT.E. JohnsonS.W. Gamma-hydroxybutyrate is a GABAB receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons.J. Pharmacol. Exp. Ther.1998287126126510.1016/S0022‑3565(24)37787‑0 9765346
     [Google Scholar]
  126. LabouèbeG. LomazziM. CruzH.G. CretonC. LujánR. LiM. YanagawaY. ObataK. WatanabeM. WickmanK. BoyerS.B. SlesingerP.A. LüscherC. RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area.Nat. Neurosci.200710121559156810.1038/nn2006 17965710
     [Google Scholar]
  127. ErhardtS. AnderssonB. NissbrandtH. EngbergG. Inhibition of firing rate and changes in the firing pattern of nigral dopamine neurons by γ-hydroxybutyric acid (GHBA) are specifically induced by activation of GABAB receptors.Naunyn Schmiedebergs Arch. Pharmacol.1998357661161910.1007/PL00005215 9686936
     [Google Scholar]
  128. FeigenbaumJ.J. HowardS. Naloxone reverses the inhibitory effect of gammahydroxybutyrate on central DA release.Neurosci. Lett.199722417174 9132694
     [Google Scholar]
  129. GessaG.L. VargiuL. CrabaiF. BoeroG.C. CaboniF. CambaR. Selective increase of brain dopamine induced by gamma-hydroxybutyrate.Life Sci.19665211921193010.1016/0024‑3205(66)90261‑X
     [Google Scholar]
  130. WaltersJ.R. RothR.H. Effect of gamma-hydroxybutyrate on dopamine and dopamine metabolites in the rat striatum.Biochem. Pharmacol.197221152111212110.1016/0006‑2952(72)90164‑5 4645883
     [Google Scholar]
  131. FeigenbaumJ. YanaiJ. KlawansH. MoonB. Differential catecholamine uptake inhibition as a possible mode of action of D-amphetamine induced locomotor activity.Res. Commun. Chem. Pathol. Pharmacol.1983392349352 6844751
     [Google Scholar]
  132. KusljicS. van den BuuseM. GogosA. Reassessment of amphetamine- and phencyclidine-induced locomotor hyperactivity as a model of psychosis-like behavior in rats.J. Integr. Neurosci.20222111710.31083/j.jin2101017 35164453
     [Google Scholar]
  133. GatleyS.J. VolkowN.D. FowlerJ.S. DeweyS.L. LoganJ. MedicalS.J.G. ChemistryJ.S.F. DepartmentsJ.L. Sensitivity of striatal [11C]cocaine binding to decreases in synaptic dopamine.Synapse199520213714410.1002/syn.890200207 7570343
     [Google Scholar]
  134. RossS. JacksonD. Kinetic properties of the accumulation of 3H-raclopride in the mouse brain in vivo.Naunyn Schmiedebergs Arch. Pharmacol.1989340161210.1007/BF00169199 2797215
     [Google Scholar]
  135. KishS.J. O’LearyG. MamelakM. McCluskeyT. WarshJ.J. ShapiroC. BiesR. YuY. PollockB. TongJ. BoileauI. Does sodium oxybate inhibit brain dopamine release in humans? An exploratory neuroimaging study.Hum. Psychopharmacol.2021365e279110.1002/hup.2791 33899252
     [Google Scholar]
  136. WilliamsJ.A. ComisarowJ. DayJ. FibigerH.C. ReinerP.B. State-dependent release of acetylcholine in rat thalamus measured by in vivo microdialysis.J. Neurosci.19941495236524210.1523/JNEUROSCI.14‑09‑05236.1994 8083733
     [Google Scholar]
  137. SteriadeM. DattaS. ParéD. OaksonG. Curró DossiR.C. Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems.J. Neurosci.19901082541255910.1523/JNEUROSCI.10‑08‑02541.1990 2388079
     [Google Scholar]
  138. SteriadeM. McCormickD.A. SejnowskiT.J. Thalamocortical oscillations in the sleeping and aroused brain.Science1993262513467968510.1126/science.8235588 8235588
     [Google Scholar]
  139. JuhászG. EmriZ. KékesiK.A. SalfayO. CrunelliV. Blockade of thalamic GABAB receptors decreases EEG synchronization.Neurosci. Lett.19941721-215515810.1016/0304‑3940(94)90685‑8 8084524
     [Google Scholar]
  140. WilliamsS.R. TurnerJ.P. CrunelliV. Gamma-hydroxybutyrate promotes oscillatory activity of rat and cat thalamocortical neurons by a tonic GABAB receptor-mediated hyperpolarization.Neuroscience199566113314110.1016/0306‑4522(94)00604‑4 7637863
     [Google Scholar]
  141. FerrarelliF. Sleep abnormalities in Schizophrenia: State of the art and next steps.Am. J. Psychiatry20211781090391310.1176/appi.ajp.2020.20070968 33726524
     [Google Scholar]
  142. CohenS. GoldsmithD.R. NingC.S. AddingtonJ. BeardenC.E. CadenheadK.S. CannonT.D. CornblattB.A. KeshavanM. MathalonD.H. PerkinsD.O. SeidmanL.J. StoneW.S. TsuangM.T. WoodsS.W. WalkerE.F. MillerB.J. Sleep disturbance, suicidal ideation and psychosis-risk symptoms in individuals at clinical high risk for psychosis.Psychiatry Res.202434111614710.1016/j.psychres.2024.116147 39197223
     [Google Scholar]
  143. FerrarelliF. Sleep spindles as neurophysiological biomarkers of schizophrenia.Eur. J. Neurosci.20245981907191710.1111/ejn.16178 37885306
     [Google Scholar]
  144. KaskieR.E. GillK.M. FerrarelliF. Reduced frontal slow wave density during sleep in first-episode psychosis.Schizophr. Res.201920631832410.1016/j.schres.2018.10.024 30377012
     [Google Scholar]
  145. PoeS.L. BrucatoG. BrunoN. ArndtL.Y. Ben-DavidS. GillK.E. ColibazziT. KantrowitzJ.T. CorcoranC.M. GirgisR.R. Sleep disturbances in individuals at clinical high risk for psychosis.Psychiatry Res.201724924024310.1016/j.psychres.2016.12.029 28126579
     [Google Scholar]
  146. AyersN. McCallW.V. MillerB.J. Sleep problems, suicidal ideation, and psychopathology in first-episode psychosis.Schizophr. Bull.202450228629410.1093/schbul/sbad045 37086485
     [Google Scholar]
  147. KantrowitzJ.T. OakmanE. BickelS. CitromeL. SpielmanA. SilipoG. BattagliaJ. JavittD.C. The importance of a good night’s sleep: An open-label trial of the sodium salt of γ-hydroxybutyric acid in insomnia associated with schizophrenia.Schizophr. Res.20101201-322522610.1016/j.schres.2010.03.035 20435443
     [Google Scholar]
  148. LatasterJ. Myin-GermeysI. LiebR. WittchenH.U. van OsJ. Adversity and psychosis: A 10‐year prospective study investigating synergism between early and recent adversity in psychosis.Acta Psychiatr. Scand.2012125538839910.1111/j.1600‑0447.2011.01805.x 22128839
     [Google Scholar]
  149. GomesF. GraceA. Prefrontal cortex dysfunction increases susceptibility to schizophrenia-like changes induced by adolescent stress exposure.Schizophr. Bull.2017433S24810.1093/schbul/sbx022.097 28003467
     [Google Scholar]
  150. WalkerE.F. TrotmanH.D. PearceB.D. AddingtonJ. CadenheadK.S. CornblattB.A. HeinssenR. MathalonD.H. PerkinsD.O. SeidmanL.J. TsuangM.T. CannonT.D. McGlashanT.H. WoodsS.W. Cortisol levels and risk for psychosis: Initial findings from the North American prodrome longitudinal study.Biol. Psychiatry201374641041710.1016/j.biopsych.2013.02.016 23562006
     [Google Scholar]
  151. DornbiererD.A. BoxlerM. VoegelC.D. StuckyB. SteuerA.E. BinzT.M. BaumgartnerM.R. BaurD.M. QuednowB.B. KraemerT. SeifritzE. LandoltH.P. BoschO.G. Nocturnal gamma-hydroxybutyrate reduces cortisol-awakening response and morning kynurenine pathway metabolites in healthy volunteers.Int. J. Neuropsychopharmacol.2019221063163910.1093/ijnp/pyz047 31504554
     [Google Scholar]
  152. NavaF. PremiS. ManzatoE. CampagnolaW. LucchiniA. GessaG.L. Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: An open study vs. diazepam.Am. J. Drug Alcohol Abuse200733337939210.1080/00952990701315046 17613965
     [Google Scholar]
  153. PaquinV. LapierreM. VeruF. KingS. Early environmental upheaval and the risk for schizophrenia.Annu. Rev. Clin. Psychol.202117128531110.1146/annurev‑clinpsy‑081219‑103805 33544627
     [Google Scholar]
  154. PopovicD. SchmittA. KauraniL. SennerF. PapiolS. MalchowB. FischerA. SchulzeT.G. KoutsoulerisN. FalkaiP. Childhood trauma in schizophrenia: Current findings and research perspectives.Front. Neurosci.20191327410.3389/fnins.2019.00274 30983960
     [Google Scholar]
  155. HertzL. RothmanD.L. Glucose, lactate, β-hydroxybutyrate, acetate, GABA, and succinate as substrates for synthesis of glutamate and GABA in the glutamine-glutamate/GABA cycle.The Glutamate/GABA-Glutamine Cycle. SchousboeA. SonnewaldU. ChamSpringer201694210.1007/978‑3‑319‑45096‑4_2
     [Google Scholar]
  156. f KaufmanE.E. Metabolism and distribution of gammahydroxybutyrate in the brain.Gammahydroxybutyrate: Molecular, Functional and Clinival Aspects. TunnicliffG. CashC.D. London and New YorkTaylor and Francis2002
     [Google Scholar]
  157. YungJ.H.M. YeungL.S.N. IvovicA. TanY.F. JentzE.M. BatchuluunB. GohilH. WheelerM.B. JosephJ.W. GiaccaA. MamelakM. Prevention of lipotoxicity in pancreatic islets with gammahydroxybutyrate.Cells202211354510.3390/cells11030545 35159354
     [Google Scholar]
  158. HallerC. MendeM. SchuierF. SchuhR. SchröckH. KuschinskyW. Effect of γ-hydroxybutyrate on local and global glucose metabolism in the anesthetized cat brain.J. Cereb. Blood Flow Metab.199010449349810.1038/jcbfm.1990.91 2347880
     [Google Scholar]
  159. DienelS.J. EnwrightJ.F. HoftmanG.D. LewisD.A. Markers of glutamate and GABA neurotransmission in the prefrontal cortex of schizophrenia subjects: Disease effects differ across anatomical levels of resolution.Schizophr. Res.2020217869410.1016/j.schres.2019.06.003 31296415
     [Google Scholar]
  160. VeeraiahP. NoronhaJ.M. MaitraS. BaggaP. KhandelwalN. ChakravartyS. KumarA. PatelA.B. Dysfunctional glutamatergic and γ-aminobutyric acidergic activities in prefrontal cortex of mice in social defeat model of depression.Biol. Psychiatry201476323123810.1016/j.biopsych.2013.09.024 24239130
     [Google Scholar]
  161. FerraroL. TanganelliS. O’ConnorW.T. FrancesconiW. LocheA. GessaG.L. AntonelliT. γ‐Hydroxybutyrate modulation of glutamate levels in the hippocampus: An in vivo and in vitro study.J. Neurochem.200178592993910.1046/j.1471‑4159.2001.00530.x 11553667
     [Google Scholar]
  162. DornbiererD.A. ZölchN. BaurD.M. HockA. StuckyB. QuednowB.B. KraemerT. SeifritzE. BoschO.G. LandoltH.P. Nocturnal sodium oxybate increases the anterior cingulate cortex magnetic resonance glutamate signal upon awakening.J. Sleep Res.2023324e1386610.1111/jsr.13866 36869598
     [Google Scholar]
  163. FeigensonK.A. KusnecovA.W. SilversteinS.M. Inflammation and the two-hit hypothesis of schizophrenia.Neurosci. Biobehav. Rev.201438729310.1016/j.neubiorev.2013.11.006 24247023
     [Google Scholar]
  164. GermannM. BrederooS.G. SommerI.E.C. Abnormal synaptic pruning during adolescence underlying the development of psychotic disorders.Curr. Opin. Psychiatry202134322222710.1097/YCO.0000000000000696 33560023
     [Google Scholar]
  165. KuhnS.A. van LandeghemF.K.H. ZachariasR. FärberK. RappertA. PavlovicS. HoffmannA. NolteC. KettenmannH. Microglia express GABA B receptors to modulate interleukin release.Mol. Cell. Neurosci.200425231232210.1016/j.mcn.2003.10.023 15019947
     [Google Scholar]
  166. CrunelliV. LerescheN. Action of γ-hydroxybutyrate on neuronal excitability and underlying membrane conductances.Gamma-Hydroxybutyrate. TunnicliffG. CashC.D. London and New YorkTaylor and Francis200275110
     [Google Scholar]
  167. KleinC. KemmelV. TalebO. AunisD. MaitreM. Pharmacological doses of gamma-hydroxybutyrate (GHB) potentiate histone acetylation in the rat brain by histone deacetylase inhibition.Neuropharmacology200957213714710.1016/j.neuropharm.2009.04.013 19427877
     [Google Scholar]
  168. LeusN.G.J. ZwindermanM.R.H. DekkerF.J. Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation.Curr. Opin. Chem. Biol.20163316016810.1016/j.cbpa.2016.06.019 27371876
     [Google Scholar]
  169. XiaM. ZhaoQ. ZhangH. ChenY. YuanZ. XuY. ZhangM. Proteomic analysis of HDAC3 selective inhibitor in the regulation of inflammatory response of primary microglia.Neural Plast.2017201711310.1155/2017/6237351 28293439
     [Google Scholar]
  170. SubburajuS. ColemanA.J. CunninghamM.G. RuzickaW.B. BenesF.M. Epigenetic regulation of glutamic acid decarboxylase 67 in a hippocampal circuit.Cereb. Cortex201727115284529310.1093/cercor/bhw307 27733539
     [Google Scholar]
/content/journals/cn/10.2174/011570159X377481250526110256
Loading
Can Sodium Oxybate Mitigate the Symptoms of Schizophrenia?
Curr. Neuropharmacol. 24, 325 (2026); https://doi.org/10.2174/011570159X377481250526110256
/content/journals/cn/10.2174/011570159X377481250526110256
/content/journals/cn/10.2174/011570159X377481250526110256
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cholinergic agonist; dopaminergic antagonist; GABA; glutamate; oxidative stress; psychological stress; Schizophrenia; sleep; sodium oxybate

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test